ReviewLife (Basel, Switzerland)2025
Multivessel Coronary Artery Disease in Cancer Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients have a higher propensity for adverse cardiovascular outcomes, primarily due to the toxic effects of chemotherapeutic agents and radiation therapy. The objective of this systematic review and meta-analysis was to investigate the proportion of multivessel coronary artery disease (MVD) in cancer compared to non-cancer patients undergoing percutaneous coronary intervention (PCI). We systematically screened the literature for studies providing data on MVD in patients with and without cancer who underwent PCI. Seventeen observational studies (5200 patients with active cancer/history of cancer and 55,146 control patients without cancer) were included in the analysis. Most studies did not show statistically significant differences in the incidence of MVD. Overall, there was no significant difference in MVD occurrence in the cancer group (risk ratio [RR]: 1.03; 95% confidence intervals [CI]: 0.99-1.08;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.